Biomarkers
Biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.
For any unfamiliar terms, please visit:
https://www.merriam-webster.com/medical
This table is searchable and sortable. Just click on a company logo to go to the company website or on the ad/banner/video to see an enlarged view. Simply click outside the image to return to normal view. The first row shows what a complete listing would look like. Click here to find out how you can get a company listing.
To return to the table listing all of our Directories, click here.
How to search PMM Directories
Simply enter your search terms into the search box located at the top of each Directory and then click on the blue search icon to the right. Search terms could include the name of a medical condition, type of innovation/technology, or company name, or any terms related to the condition or innovation type that you are interested in. For example, you could enter a term such as ´app´, ´gene´, ´cancer´, ´dementia´, ´epidermolysis bullosa´, or ´Pfizer´. You can also sort each of the columns alphabetically simply by clicking on the arrows that will appear to the right of the column´s name when you hover the mouse on that cell.
| Organization | Country | Innovation | Company Info | Logo | Ad/Banner/Video | Company News |
|---|---|---|---|---|---|---|
| Personalize My Medicine | UK | Platform for medical innovation | PMM keeps you informed about the latest advancements in medical innovation with a focus on personalized and precision medicine approaches to healthcare |  |  | Subscribe to PMM's free monthly newsletter here! |
| Abbvie | US | Building and using their understanding of biomarkers in solid tumors to guide the development of immunotherapies, targeted small molecule inhibitors and antibody drug conjugates (ADCs) | ||||
| Abiosciences | US | Using single-cell genomics and bioinformatics to gain molecular insights into human diseases and translate them into effective therapeutics and diagnostics | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Acobiom | France | identification of new biomarkers and in the development of innovative Diagnostics in Translational Research and Precision Medicine | ||||
| Active Motif | US | Developer of life science tools intended to bring epigenetics into the translational and precision medicine segments | ||||
| Adesis | US | Compounds developed for clients have found use in life-enhancing oncology, anti-infective, animal treatment, central nervous system, immunotherapy, therapeutic, ophthalmic, biomarkers, skin care, catalysts and other applications | ||||
| Advanced Cell Diagnostics | US | developing cell- and tissue-based research and diagnostic tests for personalized medicine | ||||
| Akoya Biosciences | US | comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Alto Neuroscience | US | artificial intelligence (AI)-enabled platform measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to | ||||
| APIS Assay Technologies Ltd. | UK | Biomarker Industrial Research Programme. This structured R&D programme undertakes industrial research on biomarker-based diagnostic assays, targeting oncology, inflammatory, cardiovascular, infectious disease and inherited disease areas | ||||
| Augurex Life Sciences Corp. | Canada | commercialized blood test, the 14-3-3η Blood Test, can detect Rheumatoid Arthritis earlier, show treatment effectiveness, and reveal joint damage | ||||
| Bill & Melinda Gates Medical Research Institute | US | drugs, biologics, and vaccines | ||||
| BioAgilytix | US | services for biomarker, immunogenicity, pharmacokinetics (PK), and cell-based assays and diagnostic testing services | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| BioArctic | Sweden | focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company is also developing a potential treatment for Complete Spinal Cord Injury | ||||
| Biocare Medical | US | supplier and developer of primary antibodies and automated immunohistochemistry (IHC) medical equipment for lab testing | ||||
| Biocept Inc. | US | CNSide™ assay provides enhanced detection and analysis of tumor cells and cell-free DNA from cerebrospinal fluid (CSF) | ||||
| Biocrates | Austria | metabolomics kits allow for the analysis of up to 630 metabolites across multiple analyte classes in a single run | ||||
| Biodesix Inc | US | diagnostic services for biopharma partners, including biomarker discovery, assay design and development, fit-for-purpose regulatory strategies, clinical trial testing, commercialization, and companion diagnostic capabilities | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| BioIVT | US | provider of high-quality biological specimens and value-added services, specializing in control and disease state samples including human and animal tissues, cell products, blood and other biofluids | ||||
| Biological Dynamics | US | proprietary Verita™ platform simplifies access to biomarkers, nanoparticles, and nucleic acids, enabling differentiated multiomic applications | ||||
| BioSyntagma | US | Molecular Fingerprint™ (mPrint™) platform creates a comprehensive, multi-omic, and spatial profile of tissue to enhance understanding of patient’s cancer so they can be matched with relevant therapies to prevent acquired drug resistance. bioSyntagma’s mPrint™ platform for implementation of precision medicine for cancer treatment | ||||
| CellCarta | Canada | offers access to integrated analytical platforms in immunology (immune monitoring), histopathology, proteomics and genomics, as well as digital pathology/AI and sample management, logistics and kitting services | ||||
| Canopy Biosciences | US | proprietary platform ChipCytometry™ is an image-based high-plex proteomics instrument for spatial biology research that allows quantification of virtually unlimited protein biomarkers on a sample with true single-cell resolution | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Centre for Human Drug Resistance | Netherlands | range of high quality, data intensive clinical pharmacology services | ||||
| Clarigent Health | US | Clairity software unites vocal biomarkers with self-assessment scales and clinical judgment to generate individual progress trends, risk alerts, and population insights to mental healthcare providers | ||||
| Coral Biotechnology Inc. | US | provides contract research services for molecular analysis in addition to clinical trial and bio-marker investigation studies. The company also provides laboratory studies for gene expression analysis, genomics and epigenetics | ||||
| CorDx | US | rapid testing and point-of-care medical device solutions used in the detection of infectious disease such as COVID-19, pregnancy, drugs of abuse, biomarkers, and more | ||||
| CytomX Therapeutics | US | Develops cancer immunotherapies, drug conjugates (PDCs), T-cell engaging Probody bispecifics and ProCAR-NK cell therapies based on Protease-Activated Antibodies, 'Probodies' | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Denali Therapeutics | US | Developing therapies to treat neurodegenerative diseases | ||||
| Denovo Biopharma | US | industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy or side effects | ||||
| Discovery Life Sciences | US | highly characterized human biospecimens and cellular starting materials integrated with expert multi-omic analytical services to advance cell and gene therapy and precision medicine programs for cancer, infectious disease, and other complex conditions | ||||
| Dyve Biosciences | US | transdermal platform allows us to formulate a broad range of molecules without compromising pharmacokinetics | ||||
| Early is Good | US | tests to enable early, accurate, and widely accessible detection of renal system diseases, including bladder, kidney, and prostate cancers, by assessing specific biomarkers found in urine | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Engitix Therapeutics | UK | using their human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours | ||||
| Envol Biomedical | US | preclinical and clinical pharmacology services for drug discovery, toxicology and early clinical trials in support of small molecules and biologics | ||||
| Ethos Biosciences | US | providing diagnostic tools for scientists and practitioners | ||||
| Exosome Diagnostics | US | minimally invasive molecular diagnostics in blood and urine to enable doctors to select optimal therapies for cancer and other diseases | ||||
| Firalis | Switzerland | Development BM-based diagnostic, prognostic and theranostic tools: RUO Kits (Research-Use-Only), based on validated innovative biomarkers and IVD Tools (In Vitro Diagnostic), based on a combination of clinically qualified biomarkers | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Flagship Biosciences | US | spatial biology and biomarker services | ||||
| FOXO Technologies | US | offers leading supervised machine learning and artificial intelligence technologies to identify epigenetic biomarkers that measure current states of health and aging | ||||
| Fujirebio Diagnostics AB | Japan | developing new technologies and unique biomarkers with high clinical value | ||||
| Gritstone Bio | US | developing immunotherapies for cancers and infectious diseases | ||||
| Ikena Oncology | US | pipeline of programs focused on genetically defined or biomarker-driven cancers to target specific patient populations | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Immunexpress | US | SeptiCyte® quantifies the specific molecular biomarkers from a patient's immune system ('host response'). Biomarkers capture signals from a patient's immune system in response to infection. These biomarkers may hold the key to early detection of sepsis, as well as guiding the use and timing of drugs and other therapies | ||||
| Immatics | Germany | pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry | ||||
| Immunovia | Sweden | Tests based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease, thereby forming a unique “disease biomarker signature” | ||||
| IROA Technologies | US | develop metabolomic workflow tools that automate the measurement of biochemicals using internal standards | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| IsoPlexis | US | develops a single-cell detection system identifying patient immune response | ||||
| Ixico | UK | neuroimaging and digital biomarker solutions and data analysis services | ||||
| KCAS Bioanalytical & Biomarker Services | US | bioanalytical, biomarker, cellular and molecular assay services and clinical kitting and storage management | ||||
| Kiromic | US | proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases. Kiromic is in the process of developing a multi-indication allogeneic CAR-T cell therapy that exploits the natural potency of Gamma Delta T-cells to target solid cancers | ||||
| Known Medicine | US | machine learning-based sensitivity assay, paired with -omics data, allows identification of predictive biomarkers and the most likely responders for new drugs | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Kura Oncology | US | pipeline includes tipifarnib, a farnesyl transferase inhibitor, currently in a registration-directed clinical trial and KO-539, a menin-MLL inhibitor, currently in a Phase 1/2A clinical trial | ||||
| Laureate Institute for Brain Research | US | developing potential biomarkers (including genetic sampling, anatomical MRI, MRI spectroscopy, and functional magnetic resonance imaging (fMRI)) of patient groups defined by partitioning of clinical phenotypes to be added to the longitudinal clinical studies | ||||
| Linus Bio | US | pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology | ||||
| MedQIA, LLC | US | multidisciplinary biomarker R&D program which is a collaborative effort encompassing imaging physics, computer vision, pattern classification, biostatistics, and radiological sciences | ||||
| Meso Scale Diagnostics LLC | US | MULTI ARRAY technology enhances medical research and drug development by enabling researchers to profile many biomarkers simultaneously in a single sample without compromising assay performance | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Morphic Therapeutic | US | Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases | ||||
| MPI Research | US | strong presence within the cellular and molecular biology fields, biomarkers, and gene therapy | ||||
| NeuropointDx | US | compound safety screening division Stemina Biomarker Discovery used to develop metabolomics platform for identifying differences in metabolism in children with Autism Spectrum Disorder (ASD) and other neurological disorders | ||||
| Nordic Bioscience A/S | Denmark | Their Protein Fingerprint technology is usedto identify fragments of the ECM that are released from affected tissues and develop blood-based biomarker assays to quantify disease activity with the aim of precision medicine | ||||
| Olaris | US | leveraging metabolomics and machine learning for the discovery and development of its myOLARIS™ diagnostics products, which aim to optimize treatments and outcomes for individual patients. Metabolite diagnostics empower therapeutic selection, treatment effectiveness monitoring, disease diagnosis, and target identification across indications and therapeutics areas, including oncology, solid-organ transplant, and neurodegeneration | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Olink Therapeutics | Sweden | high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome | ||||
| OncoDNA | Belgium | provides clinical guidance for the treatment and real-time monitoring of late stage cancer patients and supports research and drug development in cancer and genetic disease | ||||
| Oncorus | US | IV-administered, self-amplifying RNA medicines for the treatment of cancer | ||||
| Oryzon Genomics | Spain | development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology | ||||
| Pax Neuroscience | US | development and commercialization of blood tests for depression diagnosis and for antidepressant response. These tests are based on novel protein biomarkers derived from hypothesis-driven data sets | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Pieris | US | Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma, and a half-life-optimized Anticalin to treat anemia | ||||
| PrecisionLife | UK | Generating understanding of the biology driving chronic diseases, stratifying patient populations to define new subgroups of patients | ||||
| Proteomedix AG | Switzerland | Non-invasive diagnostic tests to detect and assess the prognosis of cancer, as well as to match patients with safer and more effective therapies. The first product is a blood-based test for the early diagnosis of prostate cancer | ||||
| Pyxant Labs | US | directly supporting research into cure for hepatitis, antiviral therapeutics for HIV, a fundamental understanding of Alzheimer’s Disease, antisense therapeutics, and therapeutics for COVID-19 | ||||
| RareCyte | US | Spatial Biology and Liquid Biopsy solutions | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Renalytix | US | proprietary solution that successfully enables early-stage, progression risk assessment for kidney health | ||||
| REPROCELL | Japan | access to human tissues (BioServe) and human tissue testing (Biopta), in addition to stem cell culture media, reprogramming technologies, reagents, and iPSC-derived cell types (Stemgent) | ||||
| Rules-Based Medicine a Q² Solutions Company | US | biomarker services and a novel whole blood immunophenotyping device (TruCulture®). RBM’s internally developed and manufactured immunoassays based on Multi-Analyte Profiling (MAP) and Single-Molecule Array (SimoaTM) ultrasensitive immunoassay technology | ||||
| Sapient | US | platform combines next-gen rapid liquid chromatography-mass spectrometry (rLC-MS) technologies – able to assay >11,000 small molecule biomarkers per biosample – computational learning, and an expansive proprietary Human Biology Database with data from several hundred thousand biosamples | ||||
| Sengenics | US | using their patented KREX protein folding technology to discover autoantibody biomarker signature for drug response prediction, patient stratification, and development of companion diagnostics | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Sutro Biopharma | US | next-generation cancer therapeutics - antibody drug conjugates, bispecific antibodies and cytokine derivatives | ||||
| Synexa Life Sciences | Netherlands | expertise in biomarker selection and panel design for each phase of clinical development | ||||
| Tango Therapeutics | US | developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients | ||||
| Target Discovery | US | Innovative testing strategies leveragING the latest advances in analytical instrumentation, surface chemistry, microfluidics, nanotechnology, signal processing, and machine learning | ||||
| Theta Biomarkers | Greece | offer comprehensive analysis of biological samples with 10+ validated protocols and 50+ fit for purpose methods | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| TRON-Mainz | Germany | identifying “omics”-based biomarkers and developing personalized therapies | ||||
| QIBA | US | advancing quantitative imaging and the use of imaging biomarkers | ||||
| Quant Biomarkers | Switzerland | using artificial intelligence (AI) to develop personal biomarker panels for the targeted and early detection of chronic conditions to achieve a healthy lifespan | ||||
| Quanterix | US | digitizing biomarker analysis with the goal of advancing the science of precision health | ||||
| Quibim | Spain | develops quantitative biomarkers, companion diagnostics and other imaging tools for systems biology applications, from immuno-oncology to neurology | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Scipher Medicine | US | platform that identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias | ||||
| Singulex | US | Singulex Clarity system is a fully-automated, in vitro diagnostics platform powered by Single Molecule Counting technology | ||||
| Tecan | Switzerland | products for application in agriculture, forensic solutions, analytical chemistry, cell biology, drug discovery, genomic solutions, protein science solutions, ELISA solutions, and synthetic biology. Its systems and components are used widely in clinical diagnostics and basic and translational research | ||||
| Ultivue | US | Developing products and services using spatial phenomics that utilize emerging knowledge of human biology and enable the data-driven development of personalized cancer therapies | ||||
| Wren Therapeutics | UK | drug discovery and development for protein misfolding diseases. Developing a broad pipeline of small molecule and antibody therapeutics, as well as diagnostics, spanning neurology, ophthalmology, and metabolic diseases | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||